Business

Aegerion Pharmaceuticals stock rises despite net loss, thanks to revenue forecast

Aegerion’s Juxtapid drug is used to treat cholesterol disease.
Aegerion’s Juxtapid drug is used to treat cholesterol disease.istockphoto.com

This is a summary. To read the whole story subscribe to BostonGlobe.com

Aegerion Pharmaceuticals Inc. rose on Tuesday and Wednesday even after it posted a wider net quarterly loss of $18.9 million amid higher expenses. Aegerion raised its revenue expectations for the year to reflect recent results from the launch of its genetic cholesterol-disease drug, Juxtapid, its sole product on the market. Aegerion raised its net revenue expectation to $30 million to $35 million, from earlier guidance of $15 million to $25 million.

Full story for BostonGlobe.com subscribers.

Get the full story with unlimited access to BostonGlobe.com.

Just 99 cents for four weeks.

Share